Axium Healthcare Puerto Rico is proud to announce it is now dispensing ELAHERE (mirvetuximab soravtansine-gynx) injection, for intravenous use. This is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate that is indicated for:
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico Specialty Pharmacy, recently shared what access to ELAHERE means for oncology patient in PRs. “ELAHERE is a new kind of treatment called an antibody-drug conjugate (ADC) that is different from traditional chemotherapies and designed to treat cancer in a targeted way. As the leading specialty pharmacy on the island, Axium continues adding innovative therapies to our portfolio. We are proud to add ELAHERE to our treatment options for patients who have not responded to previous treatments.”
At Axium Healthcare Puerto Rico our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Oncology. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare Pharmacy Puerto Rico:
At Axium Healthcare Puerto Rico, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare Puerto Rico offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare Puerto Rico services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, ImmunoGen aims to disrupt the progression of cancer and offer patients more good days. ImmunoGen calls this their commitment to TARGET A BETTER NOW™. Learn more about who they are, what they do, and how they do it at www.immunogen.com.
ELEHERE™ is a trademark of ImmunoGen, Inc. Any other trademarks referred to in this release are the property of their respective owners.